Blueprint Medicines
https://www.blueprintmedicines.comBlueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations
Pipeline | Blueprint Medicines
https://www.blueprintmedicines.com/pipeline01.12.2021 · Blueprint Medicines and Roche have co-exclusive rights to develop and commercialize pralsetinib in the U.S., and Roche has exclusive rights to develop and commercialize pralsetinib outside the U.S., excluding the CStone territory. 5 Received accelerated approval in the U.S. for the treatment of adults with metastatic RET fusion-positive NSCLC.